Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28;352(17):1779–1790. doi:10.1056/NEJMoa051113
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr;7(4):387–397. doi:10.1016/j.ccr.2005.03.023
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar 19-25;365(9464):1054–1061. doi:10.1016/S0140-6736(05)71142-9
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005 Apr 28;434(7037):1144–1148. doi:10.1038/nature03546
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15;108(10):3472–3476. doi:10.1182/blood-2006-04-018879
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013 Dec 19;369(25):2391–2405. doi:10.1056/NEJMoa1312542
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667–679. doi:10.1182/blood-2016-10-695940
   PubMed Web of Science ®Google Scholar
• Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005 04/01;105(7):2664–2670. doi:10.1182/blood-2004-09-3426
   PubMed Web of Science ®Google Scholar
• Nand S, Messmore H, Fisher SG, et al. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol. 1990;34(1):32–36. doi:10.1002/ajh.2830340108
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014 Apr;40(3):348–358. doi:10.1055/s-0034-1370794
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007 Jan 1;109(1):68–76. doi:10.1002/cncr.22365
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN landmark survey. BMC Cancer. 2016 Feb 27;16:167. doi:10.1186/s12885-016-2208-2
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098–4103. doi:10.1200/JCO.2012.42.3863
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep;100(9):1139–1145. doi:10.3324/haematol.2014.119545
   PubMed Web of Science ®Google Scholar
• Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643–651. doi:10.1001/jamaoncol.2015.1590
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4(5):652–659. doi:10.1001/jamaoncol.2017.5818
   PubMed Web of Science ®Google Scholar
• Passamonti F, Kiladjian J-J, Vannucchi AM, et al. ReTHINK: a randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients. J Clin Oncol. 2016;34(15_suppl):TPS7080–TPS7080. doi:10.1200/JCO.2016.34.15_suppl.TPS7080
   Web of Science ®Google Scholar
• Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016 Jul;101(7):821–829. doi:10.3324/haematol.2016.143644
   PubMed Web of Science ®Google Scholar
• Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26;130(17):1889–1897. doi:10.1182/blood-2017-05-785790
   PubMed Web of Science ®Google Scholar
• Geyer H, Mesa RA. Approach to MPN symptom assessment. Curr Hematol Malig Rep. 2017 Oct;12(5):381–388. doi:10.1007/s11899-017-0399-5
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008 Jan;22(1):14–22. doi:10.1038/sj.leu.2404955
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–770. doi:10.1200/JCO.2010.31.8436
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for myeloproliferative neoplasms research and treatment). Blood. 2010 Mar 4;115(9):1703–1708. doi:10.1182/blood-2009-09-245837
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1;29(4):392–397. doi:10.1200/JCO.2010.32.2446
   PubMed Web of Science ®Google Scholar
• Szuber N, Mudireddy M, Nicolosi M, et al. 3023 mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data Among disease subgroups. Mayo Clin Proc. 2019 Apr;94(4):599–610. doi:10.1016/j.mayocp.2018.08.022
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Sep;27(9):1874–1881. doi:10.1038/leu.2013.163
   PubMed Web of Science ®Google Scholar
• Price GL, Davis KL, Karve S, et al. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One. 2014;9(3):e90299. doi:10.1371/journal.pone.0090299
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 Oct 16;124(16):2507–2513. quiz 2615. doi:10.1182/blood-2014-05-579136
   PubMed Web of Science ®Google Scholar
• Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014 Jun 12;123(24):3803–3810. doi:10.1182/blood-2013-09-527903
   PubMed Web of Science ®Google Scholar
• Brochmann N, Flachs EM, Christensen AI, et al. Health-related quality of life in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Cancers (Basel). 2020 Nov 28;12(12):3565. doi:10.3390/cancers12123565
   PubMed Web of Science ®Google Scholar
• ElNahass YH, Mahmoud HK, Mattar MM, et al. MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients. Leuk Lymphoma. 2018;59(4):844–854. doi:10.1080/10428194.2017.1365852
   PubMed Web of Science ®Google Scholar
• Yassin MA, Taher A, Mathews V, et al. MERGE: a multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Med. 2020 Jul;9(13):4512–4526. doi:10.1002/cam4.3004
   PubMed Web of Science ®Google Scholar
• Bartoszko J, Panzarella T, Lau A, et al. Effect of Red blood cell transfusion dependence on the natural history of myeloproliferative neoplasm-associated myelofibrosis. Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e151–e156. doi:10.1016/j.clml.2015.09.001
   PubMedGoogle Scholar
• Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011 Jan;96(1):167–170. doi:10.3324/haematol.2010.031831
   PubMed Web of Science ®Google Scholar